Skip to main content
Caplight Logo









KBP Biosciences

KBP Biosciences

Private
SingaporeHealthcare & Life Scienceshttps://kbpbiosciences.com/

Last Round

M&A

Oct 16, 2023

Total Funding Raised

$76M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

KBP Biosciences is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of small-molecule therapeutics for cardiorenal and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryclinical-stage biotechsmall-molecule therapeuticsmineralocorticoid receptor antagonistMRAorgan protectionchronic kidney diseaseuncontrolled hypertensionclinical trialsdrug licensingbiotech pipelinepharma R&Daminomethylcycline antibiotic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KBP Biosciences Comparables

Compare KBP Biosciences with similar companies based on industry and business-model similarity.

KBP Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zhejiang Jixing Auto Parts Co., Ltd.
83%
Mineralys Therapeutics
83%
Tanabe Pharma Corporation
76%

KBP Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AOct 16, 2023
Series AJan 5, 2018

Key People

Founding team and executive leadership

tyler hendricks

CEO

Executive Team

James Fang

CFO

Executive Team

Julia Yang

Chief Operating Officer, Global Clinical Development, Global R D

Executive Team

KBP Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 69% MoM.

  • Feb 22, 2025

    Accused of failing to disclose crucial clinical trial results for ocedurenone.

KBP Biosciences Filings

Explore SEC and related filing metadata, where available.

KBP Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about KBP Biosciences's valuation, stock price, and market status.

Is KBP Biosciences a public or private company?

KBP Biosciences is a private company.

What is the current stock price of KBP Biosciences?

KBP Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is KBP Biosciences worth (valuation)?

Valuation information for KBP Biosciences is not publicly available.

Can I buy KBP Biosciences stock?

KBP Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was KBP Biosciences's last funding round?

KBP Biosciences's most recent funding round was M&A on October 16, 2023.

Who are the main investors in KBP Biosciences?

Key investors in KBP Biosciences include Advantech Capital, SDIC Venture Capital.

Will KBP Biosciences IPO soon?

No public IPO plans have been announced for KBP Biosciences.

How can I track KBP Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor KBP Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range44
Year Founded2011
Last FundingOct 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?